- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05126693
Short Term Follow-up of a Botulinum Toxin Intervention in Children With Spastic Cerebral Palsy
Algorithms for Patient-specific Treatment Planning in Cerebral Palsy Based on the Muscle and Tendon Architecture - Short Term Follow-up of a Botulinum Toxin Intervention in Children With Spastic Cerebral Palsy
Study Overview
Status
Conditions
Detailed Description
Aim:
This study investigates the effect of integrated Botulinum Neurotoxin A (BoNT) treatment on morphologic muscle and tendon properties (muscle length and muscle volume, assessed with a 3D ultrasound measurement), spasticity and joint stiffness (measured with an instrumented spasticity assessment), joint range of motion (measured through goniometry), muscle strength (measured using dynamometry), gait (assessed through 3D gait analysis) and gross motor function (assessed using clinical test batteries). The aim is twofold: (1) determine whether integrated BoNT treatment of the medial gastrocnemius and the semitendinosus muscle(s) leads to changes in the morphologic muscle and tendon properties of the medial gastrocnemius and the semitendinosus muscle(s), the ankle and knee range of motion, spasticity, stiffness, muscle strength and gait, and (2) determine the correlation between baseline morphologic muscle and tendon properties and the changes in the primary outcome parameters (spasticity and stiffness) following the BoNT-treatment.
Design:
The current study has a non-randomized controlled design. Because BoNT is proven an effective treatment to reduce spasticity and improve gross motor function, it cannot be clinically justified to allocate children to a non-treatment group, if a new BoNT treatment is required. Delayed BoNT treatment could rapidly increase musculoskeletal impairments. It is therefore considered unethical to temporarily withdraw BoNT treatment from patients. To compensate the lack of randomization accurate matching of groups is required. Children will be matched on diagnosis (uni/bilateral CP), GMFCS level, age and spasticity level.
BoNT-treatment:
All children in the intervention group will receive BoNT injections in the medial gastrocnemius and/or the semitendinosus muscle(s) (other muscles may also be treated as part of multilevel treatment). As part of the standard integrated treatment approach of the CP Reference Centre of the University Hospitals Leuven, the injections are followed by a period of bilateral stretching casts if indicated (below the knee walking casts and removable knee extension casts when necessary) and all children will receive intensive physical therapy and application of orthotic management following BoNT injections. The follow-up period for the current study is 8-10 weeks. During this intensive physical therapy post-BoNT, the children in the intervention group will work on individualized treatment goals. These goals will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician, which is scheduled prior to the BoNT treatment. The fulfillment of these patient-specific goals will be evaluated by the Goal Attainment Score (GAS). During the follow-up period, the treating physical therapist will be interviewed on a two-weekly basis to verify whether and to what extend the therapy is focused on the personal treatment goals. Assessments of morphologic muscle and tendon properties, spasticity, stiffness, joint range of motion, muscle strength, and gait of the participants will be performed before the BoNT injections, and 8-10 weeks after the injection. This period of 8-10 weeks follow-up post BoNT injections was found to be appropriate, since the potential effect of BoNT on gross motor function is expected to be optimal after 6-10 weeks.
Study groups:
The study will include patients who are diagnosed with spastic CP, aged between 4 and 11 years and with Gross Motor Function Classification System (GMFCS) level I-III. The intervention and control group will be group-matched based on diagnosis (uni/lateral CP), GMFCS level, age and spasticity level.
Overall exclusion criteria were: BoNT injections less than 6 months before inclusion, a treatment history that includes previous selective dorsal rhizotomy treatment or a bony surgery less than 2 years before inclusion, and limited cooperation that would prevent a proper assessment. For all enrolled children, intensive rehabilitation post BoNT injections had to be foreseen as the standard care. For the intervention group, 30 children with a clinical indication for BoNT injections in the medial gastrocnemius and/or semitendinosus muscle(s) will be recruited, while for the control group, 30 children without an indication for a specific intervention in the next 3 months will be recruited.
For the intervention group, the baseline measures will be followed by the BoNT injections combined with casting and goal-oriented physical therapy (as described above), and the follow-up assessments will be planned 8-10 weeks post BoNT injections. Baseline and follow-up assessments for the intervention groups include 3D ultrasound, the instrumented spasticity measurement, functional strength tests, and 3D gait analysis.
The children in the control group will also be assessed twice with an interval of 8-10 weeks. During the 8-10 weeks, they will continue their usual care or normal routine treatment, i.e. regular physiotherapy and orthotic devices. Baseline and follow-up assessments for the control group include 3D ultrasound, the instrumented spasticity measurement and functional strength tests.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nicky Peeters
- Phone Number: +3216341016
- Email: nicky.peeters@kuleuven.be
Study Contact Backup
- Name: Julie Uytterhoeven
- Email: julie.uytterhoeven@kuleuven.be
Study Locations
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgium, 3000
- UZ Leuven
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Confirmed diagnosis of spastic cerebral palsy
- Aged 4-11 years
- GMFCS levels I-III (GMFCS = Gross Motor Function Classification Score, expressing the overall functional level of impairment)
- Sufficient cooperation to comprehend and complete the test procedure
- Additional exclusion criterion for the intervention group specifically: Indication for BoNT injections
Exclusion Criteria:
- Non-ambulatory
- Botulinum toxin A injections six months prior to enrollment
- Lower limb surgery two years prior to enrollment
- Previous selective dorsal rhizotomy
- Presence of ataxia or dystonia
- Cognitive problems that impede measurements
- Severe co-morbidities (severe epilepsy, non-correctable visual impairment, autism spectrum disorders, mental problems that prevent comprehensiveness of the tasks)
- Hospitalization after the BoNT treatment for intensive physical therapy
- Intrathecal baclofen pump
- For the control group: new intervention planned within 3 months
- Additional exclusion criterion for the control group specifically: new intervention planned within 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
The children in the intervention group will receive BoNT injections in the medial gastrocnemius and/or the semitendinosus muscle(s).
As part of the standard treatment approach of the CP Reference Centre of the University Hospitals Leuven, the injections are followed by a period of bilateral stretching casts if indicated (below the knee walking casts and removable knee extension casts when necessary) and all children will receive intensive physical therapy and application of ankle foot orthoses following BoNT injections.
The follow-up period for the current study is 8-10 weeks.
During this intensive physical therapy period post-BoNT, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (that is scheduled prior to the BoNT injections).
|
BoNT treatment combined with a follow-up period of intensive physical therapy of 8-10 weeks.
During this intensive physical therapy post BoNT injections, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (planned prior to the BoNT injections).
|
No Intervention: Control group
This group will continue their usual care or normal routine treatment, i.e. physiotherapy and orthotic management during a period of 8-10 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in muscle volume medial gastrocnemius and semitendinosus.
Time Frame: Between baseline and 8-10 weeks after the BoNT treatment
|
Estimation of the muscle belly volume by 3D freehand ultrasonography
|
Between baseline and 8-10 weeks after the BoNT treatment
|
Change in spasticity of the medial gastrocnemius and medial hamstrings
Time Frame: Between baseline and 8-10 weeks after the BoNT treatment
|
Muscle activity of the medial gastrocnemius or medial hamstrings is recorded by surface electromyography (EMG) (millivolts) during a passive stretch of the plantar flexors or hamstrings respectively
|
Between baseline and 8-10 weeks after the BoNT treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in echo-intensity of the medial gastrocnemius and medial hamstrings
Time Frame: Between baseline and 8-10 weeks after the BoNT injections
|
Estimation of the echo-intensity by 3D freehand ultrasonography.
|
Between baseline and 8-10 weeks after the BoNT injections
|
Change in muscle belly and tendon length of the medial gastrocnemius and medial hamstrings
Time Frame: Between baseline and 8-10 weeks after the BoNT injections
|
Estimation of the muscle and tendon length by 3D freehand ultrasonography.
|
Between baseline and 8-10 weeks after the BoNT injections
|
Change in stiffness of the ankle and knee joint
Time Frame: Between baseline and 8-10 weeks after the BoNT injections
|
Stiffness is assessed by estimating the resistance (torque at a specific joint angle or work over the ROM) at the ankle or knee joint during a slow passive stretch
|
Between baseline and 8-10 weeks after the BoNT injections
|
Change in functional pre-defined goals
Time Frame: Between baseline and 8-10 weeks after the BoNT injections
|
Change in functional pre-defined treatment goals, attained by the goal attainment scale (GAS) score (from -2 to +2).
|
Between baseline and 8-10 weeks after the BoNT injections
|
Change in functional muscle strength
Time Frame: Between baseline and 8-10 weeks after the BoNT injections
|
Evaluation of functional muscle strength by the Adapted Functional Strength measure.
|
Between baseline and 8-10 weeks after the BoNT injections
|
Change of Range of motion in the ankle and knee joint
Time Frame: Between baseline and 8-10 weeks after the BoNT injections
|
ROM is measured by initial measurement units (IMU's) that are attached to the different segments.
The joint angle (degrees) is calculate as the difference in position between two IMU's
|
Between baseline and 8-10 weeks after the BoNT injections
|
Change of Range of motion in the ankle and knee joint
Time Frame: Between baseline and 8-10 weeks after the BoNT injections
|
Evaluation by goniometry expressed in degrees
|
Between baseline and 8-10 weeks after the BoNT injections
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compliance of the treatment goals during intensive physical therapy period
Time Frame: Every two weeks during the 8-10 weeks of intensive physical therapy after the BoNT injections
|
During telephone interviews every two weeks with the physical therapist, the compliance to the physical therapy with individual goals is assessed.
|
Every two weeks during the 8-10 weeks of intensive physical therapy after the BoNT injections
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kaat Desloovere, Prof. Dr., UZ Leuven
Publications and helpful links
General Publications
- Bar-On L, Aertbelien E, Molenaers G, Van Campenhout A, Vandendoorent B, Nieuwenhuys A, Jaspers E, Hunaerts C, Desloovere K. Instrumented assessment of the effect of Botulinum Toxin-A in the medial hamstrings in children with cerebral palsy. Gait Posture. 2014 Jan;39(1):17-22. doi: 10.1016/j.gaitpost.2013.05.018. Epub 2013 Jun 20.
- Bar-On L, Van Campenhout A, Desloovere K, Aertbelien E, Huenaerts C, Vandendoorent B, Nieuwenhuys A, Molenaers G. Is an instrumented spasticity assessment an improvement over clinical spasticity scales in assessing and predicting the response to integrated botulinum toxin type a treatment in children with cerebral palsy? Arch Phys Med Rehabil. 2014 Mar;95(3):515-23. doi: 10.1016/j.apmr.2013.08.010. Epub 2013 Aug 27.
- Franki I, Bar-On L, Molenaers G, Van Campenhout A, Craenen K, Desloovere K, Feys H, Pauwels P, De Cat J, Ortibus E. Tone Reduction and Physical Therapy: Strengthening Partners in Treatment of Children with Spastic Cerebral Palsy. Neuropediatrics. 2020 Apr;51(2):89-104. doi: 10.1055/s-0039-3400987. Epub 2019 Nov 27.
- Molenaers G, Fagard K, Van Campenhout A, Desloovere K. Botulinum toxin A treatment of the lower extremities in children with cerebral palsy. J Child Orthop. 2013 Nov;7(5):383-7. doi: 10.1007/s11832-013-0511-x. Epub 2013 Aug 28.
- Peeters N, Van Campenhout A, Hanssen B, Cenni F, Schless SH, Van den Broeck C, Desloovere K, Bar-On L. Joint and Muscle Assessments of the Separate Effects of Botulinum NeuroToxin-A and Lower-Leg Casting in Children With Cerebral Palsy. Front Neurol. 2020 Apr 21;11:210. doi: 10.3389/fneur.2020.00210. eCollection 2020.
- Cenni F, Monari D, Desloovere K, Aertbelien E, Schless SH, Bruyninckx H. The reliability and validity of a clinical 3D freehand ultrasound system. Comput Methods Programs Biomed. 2016 Nov;136:179-87. doi: 10.1016/j.cmpb.2016.09.001. Epub 2016 Sep 6.
- Bar-On L, Aertbelien E, Wambacq H, Severijns D, Lambrecht K, Dan B, Huenaerts C, Bruyninckx H, Janssens L, Van Gestel L, Jaspers E, Molenaers G, Desloovere K. A clinical measurement to quantify spasticity in children with cerebral palsy by integration of multidimensional signals. Gait Posture. 2013 May;38(1):141-7. doi: 10.1016/j.gaitpost.2012.11.003. Epub 2012 Dec 4.
- Molenaers, G., Desloovere, K., Eyssen, M., Decaf, J., Jonkers, I., & Cock, P. De. (1999). Botulinum toxin type A treatment of cerebral palsy: an integrated approach. European Journal of Neurology, 6, s51-s57. https://doi.org/10.1111/j.1468-1331.1999.tb00035.x
- Franki I, Desloovere K, De Cat J, Feys H, Molenaers G, Calders P, Vanderstraeten G, Himpens E, Van Broeck C. The evidence-base for basic physical therapy techniques targeting lower limb function in children with cerebral palsy: a systematic review using the International Classification of Functioning, Disability and Health as a conceptual framework. J Rehabil Med. 2012 May;44(5):385-95. doi: 10.2340/16501977-0983.
- Peeters N, Papageorgiou E, Hanssen B, De Beukelaer N, Staut L, Degelaen M, Van den Broeck C, Calders P, Feys H, Van Campenhout A, Desloovere K. The Short-Term Impact of Botulinum Neurotoxin-A on Muscle Morphology and Gait in Children with Spastic Cerebral Palsy. Toxins (Basel). 2022 Sep 29;14(10):676. doi: 10.3390/toxins14100676.
- Peeters N, Hanssen B, Bar-On L, De Groote F, De Beukelaer N, Coremans M, Van den Broeck C, Dan B, Van Campenhout A, Desloovere K. Associations between muscle morphology and spasticity in children with spastic cerebral palsy. Eur J Paediatr Neurol. 2023 May;44:1-8. doi: 10.1016/j.ejpn.2023.01.007. Epub 2023 Jan 10.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Brain Damage, Chronic
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Manifestations
- Muscle Hypertonia
- Cerebral Palsy
- Paralysis
- Muscle Spasticity
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Botulinum Toxins
Other Study ID Numbers
- S59945_C
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spastic Cerebral Palsy
-
Gazi UniversityCompletedCerebral Palsy | Cerebral Palsy, Spastic | Cerebral Palsy Spastic Diplegia | Cerebral Palsy Quadriplegic | Cerebral Palsy, MonoplegicTurkey
-
October 6 UniversityCompletedSpastic Cerebral Palsy | Spastic Hemiplegic Cerebral PalsyEgypt
-
Marmara UniversityUnknownCerebral Palsy, Spastic | Cerebral Palsy, Spastic, DiplegicTurkey
-
Burke Medical Research InstituteUniversity of Minnesota; Teachers College, Columbia UniversityRecruitingCerebral Palsy | Hemiplegic Cerebral Palsy | Spastic Hemiplegic Cerebral Palsy | Spastic Hemiplegia | Spastic HemiparesisUnited States
-
Riphah International UniversityRecruitingCerebral Palsy Spastic DiplegiaPakistan
-
Universitat de LleidaNot yet recruitingCerebral Palsy, SpasticSpain
-
Riphah International UniversityCompleted
-
Sahmyook UniversityCompletedCerebral Palsy | Gait Disorders, Neurologic | Spastic Hemiplegic Cerebral Palsy | Bilateral Spastic Cerebral PalsyKorea, Republic of
-
Sanko UniversityCompletedCerebral Palsy | Gait, Hemiplegic | Gait, Spastic | Hemiplegic Cerebral Palsy | Cerebral Palsy Spastic DiplegiaTurkey
-
Kahramanmaras Sutcu Imam UniversityCompletedCerebral Palsy | Upper Extremity Dysfunction | Muscle Strength | Cerebral Palsy, Spastic | Cerebral Palsy Spastic Diplegia | Upper Extremity FunctionsTurkey